Here you will find companies working on therapies that can alleviate acute COVID-19 disease.
We isolate and further develop natural microorganisms with immunomodulating properties and with gut protection properties to support the immune system and to protect patient against secondary infections respectively.
Development of biomarker-controlled biotechnological therapeutics against sepsis, (adrecizumab, phase 2 completed); All patients who die from a Covid-19 infection have sepsis or a septic shock (70%)
Evaluation of antiviral substances (incl. Re-purposing; perhaps participation in an EU consortium); Building up diagnostic capacity; Support for clinics and relief measures on site
Clinical trial of the drug candidate APN01 (rhACE2) to block the infection of cells by the novel virus SARS-CoV-2.
Advanced discussions with clinical centers in Europe to evaluate the human fusion protein Asunercept for the treatment of COVID-19 in two controlled Phase II clinical trials.
Atriva has a new therapeutic agent ATR-002 in clinical development for severe influenza. In the current corona crisis, Atriva Therapeutics believes it is responsible to use the potential of its drug candidate ATR-002 and to push development against COVID-19. Laboratory tests with the new coronavirus SARS-CoV-2 are currently being carried out at three German universities to confirm the antiviral effectiveness of ATR-002. In parallel, the immunomodulating effects on the new virus are being researched. If these tests confirm the suspected effectiveness, ATR-002 can be used immediately in hospital-treated patients with COVID-19.
Berlin Cures prepares phase 2 clinical trial in COVID-19 patients with the non-cytotoxic virus inhibitor BC007 (aptamer)
Development of antibody therapy (with Yumab and other partners)
Free supply of our globally unique natural product libraries and companies and university institutions with screening programs for antiviral corona active substances.
We have started to develop new drugs against the helica domain of the coronavirus. We already have validated starting points for this from existing work.
SNIM RNA therapeutic agent for antibodies against SARS-CoV-2
Part of the NIH-led initiative Accelerating COVID-19 Therapeutic Interventions and Vaccines (“ACTIV”), a public-private partnership aiming to develop a framework for prioritising vaccine and drug candidates, streamlining clinical trials, coordinating regulatory processes, and/or leveraging assets among all partners to rapidly respond to the COVID-19 and future pandemics
Joined “COVID R&D”, the global crowdsourcing initiative among top pharmaceutical company R&D leaders aimed at facilitating therapies and vaccines against COVID-19, where we will be sponsoring the pre-clinical repurposing group to channel candidate molecules from consortium members or external sources to COVID R&D
Clone and Process Development: Support for the improvement of the Airway AT-100 yield and process support in production (Airway is testing approval AT-100 as a COVID-19 therapeutic agent, Airway AT-100 was developed in the Glycotope cell line); Medium term: IGa platform for SARS virus control (consortium in planning);
Clinical trial with drug candidate IMU-838 in COVID-19 patients
Clinical trial with drug candidate IFX-1 in COVID-19
Long-term identification of viral and host cell-targeted inhibitors / therapeutics for coronavirus infections; - short-term approach to realignment; - antibody-like SARS-CoV-2 therapeutic; - Plan to invest in novel vaccination technology (one project will relate to SARS-CoV-2 vaccination).
Novartis donates millions of hydrochloroquine pills to controlled clinical trials which include Covid-19 sufferers
Development of an mRNA therapeutic to stabilize the endothelial barrier of the lung during inflammation.
Development of potential therapeutic agents, als vaccine development;
Attenuation or therapy of COVID-19 symptoms by stimulating the endogenous antiviral system.
Therapeutic drug discovery approach to validated targets
Clinical trial of the drug tocilizumab for severe COVID-19 pneumonia
Test of the COPD candidate lonodelestat (POL6014) against the respiratory distress syndrome ARDS often associated with corona infections
Development of an antiviral drug
TRON's unique expertise and infrastructure of developing innovative drugs for better patient care are available.
Development of mouse models which can be used in research for the treatment of coronavirus (SARS-CoV-2).
Antibody development against hCOV-2; Drug candidates for therapy; Antibodies for diagnostics possible